Oppilan Pharma Initiates Phase 1 Clinical Study with OPL-002
January 7, 2019

Oppilan Pharma Initiates Phase 1 Clinical Study with OPL-002

A novel S1P1 modulator for the treatment of inflammatory bowel disease

ENCINITAS, California and Cambridge, United Kingdom, January 7, 2019 – Oppilan Pharma Ltd, a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for the treatment of autoimmune diseases, today announced that it has completed dosing of the first eight subjects in a Phase 1 study evaluating OPL-002, a novel S1P1 modulator.  At the completion of the Phase 1 study, Oppilan will advance OPL-002 into development for the treatment of inflammatory bowel disease (IBD).

“We believe that there is a significant unmet need for well-tolerated, safe and effective oral therapies for people suffering from IBD,” said Chris Krueger, Chief Executive Officer of Oppilan.  “We are excited to develop OPL-002 as a new treatment option for IBD and look forward to announcing top-line clinical results from the Phase 1 study in mid-2019.”

“S1P1 modulation is a promising new, but now proven, mechanism of action for the treatment of IBD, and OPL-002 has the potential to be an important therapeutic advance,” said Dr. William Sandborn, Chair of Oppilan’s Clinical Advisory Board and a leading expert on IBD.

Oppilan was founded in September 2015 by Raju Mohan, PhD, who has also founded several other companies focused on immunology targets and the discovery and development of novel therapeutics.


About the Phase 1 Study with OPL-002

We are conducting a single ascending dose (SAD) and multiple ascending dose (MAD) study of OPL-002 in healthy volunteers.  The study is designed to evaluate the safety, tolerability, dose-response, pharmacokinetics and pharmacodynamics of OPL-002 compared to placebo.  Up to 72 subjects will be randomized into this double-blind, placebo-controlled trial.


About OPL-002

Our lead drug candidate, OPL-002, is a potent and selective modulator of sphingosine 1 phosphate receptor subtype 1 (S1P1).  S1P1 regulates lymphocyte trafficking from the lymph nodes to the peripheral blood.  S1P1 modulators block the receptor’s function and thereby sequester lymphocytes in the lymph nodes.  By sequestering lymphocytes in lymph nodes, fewer immune cells are available in the circulating blood to produce an immunological response and inflammation in the digestive tract.


About Inflammatory Bowel Disease

Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, affects as many as 1.6 million Americans and 11.2 million people worldwide, most of whom are diagnosed before the age of 35.  These chronic, life-long conditions can be treated, but not cured.  IBD is a complex disease with many contributing factors, including environmental stimuli, genetics, pathogen exposure and immune-pathogen interaction.  The end result is an excessive immunological response that leads to inflammation and disruption of the gastrointestinal tract.


About Oppilan

Oppilan Pharma Ltd is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for the treatment of inflammatory bowel disease and other autoimmune disorders.  Oppilan is registered in England and Wales with offices in Cambridge, United Kingdom and Encinitas, California.


Oppilan Pharma Contact